Drugs and patents in ATC class J04A - DRUGS FOR TREATMENT OF TUBERCULOSIS

Last updated: February 19, 2026

The patent landscape for drugs treating tuberculosis (TB) is characterized by a significant concentration of patents held by a limited number of entities, with a notable absence of broad patent protection for many established first-line TB treatments. New patent filings are primarily focused on novel compounds and drug delivery mechanisms, reflecting ongoing R&D efforts to address drug resistance and improve patient outcomes. The market is influenced by global health initiatives and the pricing strategies of generic manufacturers, which impact profitability and R&D investment.

What are the key therapeutic classes and approved drugs within ATC Class J04A?

ATC Class J04A encompasses drugs used in the treatment of tuberculosis. The primary therapeutic classes include antibiotics, anti-TB agents, and combination therapies. Approved drugs within this class are categorized by their mechanism of action and role in TB treatment regimens.

First-Line Antituberculosis Agents: These are the cornerstone of standard TB treatment.
- Isoniazid: A synthetic derivative of isonicotinic acid.
- Rifampicin (Rifampin): A semisynthetic derivative of rifamycin.
- Pyrazinamide: A synthetic pyrazine derivative.
- Ethambutol: A synthetic compound with bacteriostatic activity.
Second-Line Antituberculosis Agents: Used for multidrug-resistant TB (MDR-TB) or when first-line agents are contraindicated.
- Fluoroquinolones: Examples include levofloxacin and moxifloxacin.
- Aminoglycosides: Such as streptomycin and amikacin.
- Polypeptides: Like capreomycin.
- Thioamides: Including ethionamide and prothionamide.
- Cycloserine: A structural analog of D-alanine.
Newer Antituberculosis Agents: Developed to address drug resistance and improve efficacy.
- Bedaquiline: A diarylquinoline compound.
- Delamanid: A nitroimidazole derivative.
- Pretomanid: A nitroimidazole derivative.
Combination Therapies: Fixed-dose combinations (FDCs) of multiple antituberculosis drugs to simplify treatment regimens and improve adherence. These often combine first-line agents.

What is the patent protection status of key TB drugs?

The patent protection status for many established TB drugs is varied. First-line agents, critical for global TB control, generally have expired patent protection, leading to widespread generic availability. Newer agents, however, are subject to active patenting.

Patent Expiry for First-Line Agents

Isoniazid: Original patents expired decades ago. Generic production is common globally.
Rifampicin: Original patents expired in the late 20th century.
Pyrazinamide: Patents expired in the late 20th century.
Ethambutol: Patents expired in the late 20th century.

Active Patenting for Newer Agents

Bedaquiline (Sirturo®): Developed by Janssen Pharmaceutica. The primary compound patent was filed in the late 1990s and is subject to various international patent filings and extensions. Key patents are still active in many major markets, with expiry dates generally extending into the 2020s and beyond, depending on market and regulatory extensions. For example, US Patent 8,440,641, related to crystalline forms, was granted in 2013 and has a nominal expiry in 2031, subject to potential patent term extensions [1].
Delamanid (Deltyba®): Developed by Otsuka Pharmaceutical. Patents protecting the compound and its uses are active. For instance, European Patent EP 2 510 341 B1, covering manufacturing processes, has a nominal expiry around 2030 [2].
Pretomanid (Dovreho®): Developed by TB Alliance. Patents cover the compound and its therapeutic uses. Patent filings extend into the mid-2030s in various jurisdictions.

Patent Trends for Combination Therapies

Patents for fixed-dose combinations (FDCs) often cover specific ratios of active pharmaceutical ingredients (APIs), manufacturing processes, or novel formulations designed to improve stability, bioavailability, or patient compliance. Companies may seek to patent specific FDCs even if the individual components are off-patent.

Who are the major patent holders in the TB drug space?

The patent landscape for TB drugs is fragmented but shows concentration among pharmaceutical companies, research institutions, and global health organizations involved in drug development.

Key Patent Holders and Their Focus Areas

Janssen Pharmaceutica (Johnson & Johnson): Holds significant patents related to bedaquiline (Sirturo®), including its synthesis, crystalline forms, and therapeutic uses for multidrug-resistant TB [1].
Otsuka Pharmaceutical: Holds patents for delamanid (Deltyba®), covering its chemical structure, manufacturing processes, and treatment of TB, particularly MDR-TB [2].
TB Alliance (Global Alliance for TB Drug Development): A non-profit product development partnership that holds patents or has exclusive licenses for compounds like pretomanid, developed through its R&D programs. Their patent strategy often includes licensing agreements aimed at ensuring access in low- and middle-income countries.
Major Generic Manufacturers: While not typically originating novel compounds, companies like Cipla, Lupin, and Mylan hold process patents and formulation patents for generic versions of both first- and second-line TB drugs. They also engage in patent litigation to challenge existing patents or defend their own.
Academic and Research Institutions: Universities and research centers worldwide contribute to early-stage discovery and may hold patents on novel compounds or targets, often licensing these to pharmaceutical partners for further development.

What are the R&D trends and emerging patent filings?

R&D in TB drug development is increasingly focused on overcoming resistance mechanisms, shortening treatment durations, and improving safety profiles. Patent filings reflect these priorities.

Emerging R&D Focus Areas

Novel Drug Targets: Research into new molecular targets beyond the traditional pathways exploited by existing drugs. This includes targeting bacterial cell wall synthesis, protein synthesis, and metabolic pathways unique to Mycobacterium tuberculosis.
Combination Regimens: Development and patenting of novel combinations of existing and new drugs to combat resistance and simplify treatment. This includes the development of Paediatric-FDCs and regimens for drug-resistant TB.
Drug Resistance Mitigation: Compounds designed to overcome specific resistance mechanisms, such as those conferring resistance to fluoroquinolones or rifampicin.
Improved Drug Delivery and Formulation: Patents are being filed for novel formulations that enhance bioavailability, improve patient compliance (e.g., once-weekly dosing), and reduce side effects. Examples include liposomal formulations, nanoparticles, and long-acting injectables.
Host-Directed Therapies: Research into host-directed therapies that modulate the host immune response to TB, rather than directly targeting the bacteria. Patent activity in this nascent area is growing.

Analysis of Recent Patent Filings

A review of recent patent filings (last 5 years) indicates:

Increased activity in compounds targeting novel pathways: Filings for compounds with unique mechanisms of action, distinct from isoniazid, rifampicin, pyrazinamide, and ethambutol.
Focus on resistance: Patents specifically addressing strains of TB exhibiting resistance to existing second-line drugs, such as fluoroquinolones.
Process patents for improved manufacturing: Innovations in chemical synthesis and large-scale manufacturing processes for newer APIs like bedaquiline and delamanid, aiming to reduce production costs.
Formulation patents for patient-centric delivery: Development of new formulations for pediatric patients and improved regimens for adults to shorten treatment duration. For example, efforts to create FDCs with bedaquiline, pretomanid, and other agents.

How do global health initiatives and pricing impact the TB drug market and patent strategies?

Global health initiatives play a crucial role in shaping the TB drug market by influencing access, pricing, and R&D priorities, which in turn affects patent strategies.

Impact of Global Health Initiatives

Access to Medicines: Organizations like the World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) advocate for affordable access to essential TB medicines. This leads to pressure on pricing and encourages generic competition once patents expire.
R&D Funding and Incentives: Initiatives provide funding for research and development of new TB drugs, particularly for MDR-TB, where market incentives are traditionally lower. These initiatives often work with product development partnerships (PDPs) like the TB Alliance, which have specific patent and licensing strategies focused on access.
Tuberculosis Elimination Goals: Ambitious TB elimination targets set by global bodies encourage the development of more effective and shorter treatment regimens, driving R&D and subsequent patent filings for novel therapies.
Differential Pricing and Voluntary Licensing: PDPs and some manufacturers engage in differential pricing strategies and voluntary licensing agreements to ensure that affordable versions of patented drugs are available in low- and middle-income countries, even while patents remain in force in high-income markets.

Pricing and Competition Dynamics

Generic Competition: The expiry of patents for first-line TB drugs has led to intense competition among generic manufacturers, driving down prices. This dynamic makes it challenging for originator companies to recoup R&D investments solely through sales of off-patent drugs.
Pricing of New Drugs: The high cost of newer drugs like bedaquiline and delamanid, while essential for treating resistant TB, poses a significant access challenge in resource-limited settings. Patent protection allows originators to set higher prices. However, negotiations with global health procurers and voluntary licensing agreements are critical to expanding access.
Patent Litigation and Challenges: Generic manufacturers often challenge existing patents through litigation or by filing Paragraph IV certifications (in the US) to gain early market entry. This can lead to significant legal expenses and uncertainty regarding market exclusivity.
Market Size and Investment: The TB market, while large in terms of patient numbers, is characterized by a high proportion of patients in low-income countries, which limits the commercial profitability of R&D compared to diseases prevalent in high-income markets. This necessitates innovative funding models and patent strategies that balance commercial interests with public health needs.

Key Takeaways

The TB drug patent landscape is bifurcated, with essential first-line therapies enjoying broad generic access due to patent expiry. Newer agents, critical for addressing drug resistance, remain under patent protection, with companies like Janssen, Otsuka, and the TB Alliance holding key intellectual property. R&D is actively pursuing novel targets, resistance mitigation, and improved formulations, reflected in ongoing patent filings. Global health initiatives and pricing strategies are pivotal, balancing the need for R&D investment with essential access in high-burden countries, influencing patent strategies toward tiered pricing and licensing.

FAQs

Are there any active patents for isoniazid, rifampicin, pyrazinamide, or ethambutol? Original patents for these first-line TB drugs have long expired, allowing for widespread generic manufacturing and availability.
What is the typical expiry date for patents on newer TB drugs like bedaquiline? Patent expiry dates vary by jurisdiction and may be extended through regulatory mechanisms. For bedaquiline, key patents extend into the 2020s and beyond, with nominal expiry dates in the mid-2030s for some related patents.
Who funds the development of new TB drugs under patent? Development is funded by pharmaceutical companies, product development partnerships (PDPs) such as the TB Alliance, and government research grants. These entities often hold or license the resulting patents.
How do generic manufacturers navigate patent protection for newer TB drugs? Generic manufacturers may challenge existing patents through litigation, seek voluntary licenses from patent holders, or wait for patent expiry. They also focus on developing process and formulation patents for generic versions.
What is the role of patent evergreening in the TB drug market? While less prevalent than in some other therapeutic areas due to the market's economic structure, patent evergreening strategies, such as patenting new formulations or salts of existing compounds, can occur. However, global health priorities often emphasize access to essential medicines, which can counterbalance such strategies.

Citations

[1] United States Patent 8,440,641 B2. (2013). Crystalline forms of TMC207. Janssen Pharmaceutica NV.

[2] European Patent EP 2 510 341 B1. (2015). Process for the preparation of a compound. Otsuka Pharmaceutical Co., Ltd.

Drugs in ATC Class J04A

Subclasses in ATC: J04A - DRUGS FOR TREATMENT OF TUBERCULOSIS

Tuberculosis Drug Patents: Market Dynamics and Landscape Analysis